NASDAQ: OCGNOcugen Inc Stock
$1.18+0.00 (+0%)
Updated Apr 25, 2024
OCGN Price
$1.18
Fair Value Price
$0.04
Market Cap
$303.64M
52 Week Low
$0.35
52 Week High
$2.11
P/E
-4.54x
P/B
7.49x
P/S
23.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.04M
Earnings
-$63.08M
Gross Margin
100%
Operating Margin
-1,045.03%
Profit Margin
-1,045%
Debt to Equity
0.59
Operating Cash Flow
-$62M
Beta
1.38
Next Earnings
Jun 21, 2024
Ex-Dividend
N/A
Next Dividend
N/A
OCGN Overview
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OCGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OCGN ($1.18) is overvalued by 2,948.44% relative to our estimate of its Fair Value price of $0.04 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
OCGN ($1.18) is not significantly undervalued (2,948.44%) relative to our estimate of its Fair Value price of $0.04 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
OCGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more OCGN due diligence checks available for Premium users.
Be the first to know about important OCGN news, forecast changes, insider trades & much more!
OCGN News
Valuation
OCGN fair value
Fair Value of OCGN stock based on Discounted Cash Flow (DCF)
Price
$1.18
Fair Value
$0.04
Overvalued by
2,948.44%
OCGN ($1.18) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
OCGN ($1.18) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
OCGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OCGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.54x
Industry
15.41x
Market
40.97x
OCGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.49x
Industry
5.8x
OCGN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OCGN's financial health
Profit margin
Revenue
$6.0M
Net Income
-$9.5M
Profit Margin
-157.3%
OCGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
OCGN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$64.5M
Liabilities
$24.0M
Debt to equity
0.59
OCGN's short-term assets ($42.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OCGN's short-term assets ($42.97M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OCGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OCGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.3M
Investing
-$2.7M
Financing
$16.0k
OCGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OCGN vs Biotech Stocks
Ocugen Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.